TT X
Alternative Names: TT-XLatest Information Update: 03 Mar 2023
At a glance
- Originator Teon Therapeutics
- Class Small molecules
- Mechanism of Action 5-nucleotidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 12 Dec 2022 Early research in Unspecified in USA (Parenteral) (Teon Therapeutics pipeline, December 2022)